Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

DECIPHER LABS LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹5.49
at close · 28 Oct 2026
▲ 0.44 (+8.71%)

Latest filings

  1. Compliance certificate on dematerialized securities for Sep 2026 quarter · Compliance
  2. All 5 resolutions passed at Decipher Labs 40th AGM · Board & Shareholder Meetings
  3. 40th AGM: All 5 resolutions passed with 100% approval · Board & Shareholder Meetings
All filings ↓
Ask Nexa about DECIPHER LABS LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹14 Cr over the trailing twelve months.

Market Cap
₹6 Cr
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
-24.0%▼
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-15.4%·
ROCE (5y median)
ROE -7.7% (5y median) · margin -22.5%
Leverage
0.06·
Debt / Equity · low
Net debt ₹0.48 Cr
Revenue FY21→FY26
0.3×▼
Margin −24.5 pts
₹56 Cr → ₹14 Cr
Cash conversion
-0.30×▼
Operating cash ÷ profit · 5 yrs
₹-0 Cr on ₹1 Cr
Moves on a normal day
2.46%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#12/163
ROCE#177/183
ROE#162/166
Debt / Equity#70/166
EBITDA margin#117/165
Revenue growth#119/161
Profit growth#38/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Revenue shrinking over 5 years (−24% a year)
Erratic profits — up in only 2 of the last 5 years
Negative returns on capital — −15.4% (5-year median)
#177 of 183 in Pharmaceuticals on the latest reported figures · down from 15.3% in FY21
Over 5 years it reported ₹1.15 Cr of profit and an operating cash outflow of ₹0.35 Cr — -0.30×
Less than 60p of every ₹1 of profit arrived as cash

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from DECIPHER LABS LIMITED's filed financials and exchange disclosures

What does DECIPHER LABS LIMITED do?

DECIPHER LABS LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.

Is DECIPHER LABS LIMITED profitable?

No. Over the trailing twelve months DECIPHER LABS LIMITED reported a net loss of ₹4.30 Cr on revenue of ₹14 Cr.

Does DECIPHER LABS LIMITED pay a dividend?

Not in the latest reported year — DECIPHER LABS LIMITED's dividend payout for FY26 was nil.

Is DECIPHER LABS LIMITED debt-free?

No. It reported borrowings of ₹0.50 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹0.48 Cr after cash. Debt stands at 0.06× equity. That is lower than 58% of its 166 Pharmaceuticals peers.

How much does the DECIPHER LABS LIMITED share price move in a day?

On a typical session DECIPHER LABS LIMITED moves 2.46% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track DECIPHER LABS LIMITED's announcements?

Every NSE and BSE filing by DECIPHER LABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.